Because rilonacept is "very expensive" compared with standard treatment for acute gout flares, studies looking at the relative efficacy of the various treatment options are warranted before the drug should be widely used for this indication, Dr. Mitha stressed.
Dr. Mitha and his coinvestigators disclosed receiving grant/research support from Regeneron Pharmaceuticals, which manufactures rilonacept.